Zenosense, Inc. (ZENO) Looks to Revolutionize Early Lung Cancer Diagnosis
Less than 20 percent of lung cancer cases are detected in the relatively treatable Stage I, but healthcare technology company Zenosense, Inc. (OTCQB: ZENO) is hoping to change that. On December 16, 2014, the company announced its intention to conduct a 400 person lung cancer detection trial in collaboration with a university hospital near Madrid, Spain. Using its proprietary non-invasive, cost effective detection devices, the company aims to identify distinctive volatile organic compounds (VOCs) by analyzing patients’ exhaled breath. Zenosense is hoping to use a technique based on natural processes to decrease the costs associated with lung cancer detection. Sniffing…